If you have been reading about Hepatocyte growth factor and want a single page that covers the useful parts, this is it: definitions, context, how it is studied, and the questions that come up repeatedly.
Last reviewed on 2026-04-14. Where a claim depends on a specific study, the study is described rather than over-claimed.
Purity and identity are usually assessed with reverse-phase high-performance liquid chromatography (RP-HPLC) and mass spectrometry. RP-HPLC separates components by hydrophobicity and can estimate peptide purity. Mass spectrometry confirms molecular mass and helps detect truncations or modifications. Some laboratories also use amino acid analysis or nuclear magnetic resonance for structural verification. A certificate of analysis from a supplier may list these results, but independent verification is often recommended for critical work.
Regulatory status varies by country, and dihexa is not widely approved as a medicine. In many jurisdictions it is treated as a research chemical, which limits its legal sale, possession, and human use. Products marketed online may lack verified purity or identity, and labels can be inaccurate. Researchers typically source material from suppliers that provide analytical documentation and follow institutional safety rules. Open questions remain about long-term stability, metabolite formation, and human pharmacokinetics.
Dihexa is typically supplied as a lyophilized powder for laboratory research. Lyophilization removes water and improves stability during transport and storage. The solid is commonly stored at -20 °C or lower, desiccated, and protected from light. Repeated freeze-thaw cycles and exposure to moisture can degrade peptides, so aliquoting and sealed containers are standard practice in most laboratory settings. These handling measures apply to research-grade material and do not imply clinical suitability.
The proposed mechanism of dihexa involves activation of hepatocyte growth factor and its receptor, c-Met. In cell models, this signaling pathway is associated with dendritic spine formation and synaptic reorganization. Dihexa is described as a stabilized analog of angiotensin IV, which also interacts with related systems. However, the precise binding profile and downstream effects remain incompletely characterized. Most mechanistic evidence comes from in vitro assays and rodent studies rather than human trials.
Laboratory characterization of dihexa typically relies on reverse-phase high-performance liquid chromatography for purity and mass spectrometry for identity. These methods are standard for synthetic peptides and help distinguish the target compound from related impurities or degradation products. Because dihexa is a small peptide-like molecule, it may be susceptible to hydrolysis under certain conditions. Storage recommendations generally emphasize low temperature, dryness, and protection from light. Analytical certificates from suppliers vary in detail, so independent verification can be important for research use.
| Property | Value | Notes |
|---|---|---|
| Appearance | White to off-white powder | Typical lyophilized research form. |
| Solubility | Soluble in DMSO; limited in water | Depends on purity and salt form. |
| Storage temperature | -20 °C or lower | Desiccated and protected from light. |
| Analytical method | RP-HPLC and LC-MS | Common for purity and identity. |
| Regulatory status | Research chemical in many countries | Not widely approved as a medicine. |
Development of dihexa has been linked to academic research on synaptogenesis, the formation of new synapses. Preclinical studies in rodents have examined its effects on learning and memory tasks. These studies are often cited in discussions about cognitive enhancement, but they do not establish safety or efficacy in humans. The compound's patent and commercial history is limited, and it is not widely available through pharmaceutical channels. Most information comes from animal models and in vitro experiments. Researchers continue to explore its basic biology rather than clinical applications.
Dihexa is not approved for human use in the United States or the European Union. It is commonly sold as a research chemical, a category that may not require the same regulatory review as medicines. Buyers should note that product labels may lack independent verification of identity or purity. The legal status can vary by country, and importation may be restricted. Reliable information about sourcing and quality is often scarce. Scientific publications typically use synthesized material from laboratories rather than commercial consumer products.
Dihexa is a synthetic peptide studied in laboratory research. It is often described as an angiotensin IV analog or a hepatocyte growth factor mimetic. The compound emerged from investigations into angiotensin IV and its effects on neural pathways. It is not an approved medication, and controlled human trials are lacking. In literature and online forums, it is discussed mainly as a research chemical. Its chemical name appears as N-hexanoic-Tyr-Ile-(6-aminohexanoic amide) in some sources.
Analytical confirmation generally combines a separation method with a detection method. Reverse-phase high-performance liquid chromatography can assess purity, while mass spectrometry supports molecular identity. For research-grade material, a certificate of analysis may report a batch-specific purity value, but it does not guarantee biological activity or safety. Regulatory frameworks vary by country; many jurisdictions treat dihexa as a research chemical not intended for human consumption. Purchasers should verify local rules and supplier documentation. The absence of official standards makes independent testing and careful record-keeping important for laboratory work.
In laboratory settings, dihexa is typically handled as a research chemical rather than a pharmaceutical product. Suppliers may provide it as a lyophilized powder or in solution, and purity is often stated as a percentage determined by chromatographic analysis. Because independent verification is uncommon, researchers generally rely on certificates of analysis, which may include high-performance liquid chromatography and mass spectrometry data. The absence of pharmacopeial monographs means that identity, purity, and impurity profiles can vary between batches and suppliers.
Storage recommendations for peptides and peptide-like compounds usually emphasize low temperatures, desiccation, and protection from light. A common practice is to keep dry powder at -20 °C or below and to prepare solutions shortly before use. Repeated freeze-thaw cycles may degrade the material, so aliquoting is often advised. Solubility depends on the solvent; aqueous solubility may be limited, and organic solvents such as dimethyl sulfoxide are sometimes used for stock solutions. Stability data specific to dihexa are sparse, so general peptide handling guidelines are often applied instead.
The proposed mechanism involves interaction with the hepatocyte growth factor (HGF) system and its receptor, c-Met. Dihexa is described in some studies as an HGF mimetic, meaning it may mimic or enhance HGF-mediated signaling. Activation of c-Met can influence cell growth, survival, and cytoskeletal remodeling, pathways that intersect with synaptic plasticity. However, the precise binding targets and downstream events for dihexa are not fully established, and alternative mechanisms have been suggested.
Dihexa is a synthetic peptide with the chemical name N-hexanoic-Tyr-Ile-(6)-aminohexanoic amide, and it is structurally related to angiotensin IV, a naturally occurring peptide fragment. Researchers developed it as a modified analog intended to alter stability and activity relative to the parent peptide. Its short sequence and fatty acid chain distinguish it from many endogenous peptides, and published studies often describe it under the abbreviation dihexa. The compound is classified as a laboratory compound rather than an approved therapeutic in most jurisdictions.
Research interest in dihexa centers on its ability to promote synapse formation in cultured neurons and in some rodent experiments. These findings have been interpreted as a possible mechanism for learning and memory effects, but the evidence remains preliminary. Independent replication is limited, and study designs vary widely in species, duration, and outcome measures. Human data are scarce, so claims about cognitive enhancement in people are not supported by robust clinical evidence. The gap between laboratory signals and proven clinical benefit is substantial.
Dihexa appears in scientific literature, patent documents, and commercial catalogs under several names, which can complicate searching and verification. The compound is frequently grouped with nootropics or research chemicals, terms that describe context of use rather than regulatory approval. Such labeling may imply benefits that have not been confirmed in controlled human studies. Readers encountering promotional descriptions should distinguish between preclinical observations and established medical facts. The absence of regulatory approval is a central feature of its current status.
Dihexa is a synthetic peptide-like compound studied in preclinical research for its reported effects on synaptic growth and cognitive measures in animal models. It is often described as an analog of angiotensin IV, a naturally occurring peptide fragment. The compound has not been approved as a medicine in any major jurisdiction. Most public information comes from laboratory studies, patents, and online vendor listings rather than from large clinical trials. Its scientific status therefore differs from that of an established pharmaceutical.
=== Marriages and children === Liu Wenhui wed three wives from arranged marriages and had several children. His first marriage to Lady Gao occurred when he was only seventeen; he reportedly had no interest in her, leaving after only ten days to return to Baoding and focus on his military studies. Liu saw himself as more cosmopolitan and modern compared to his rural bride. After Liu left, Lady Gao fell into a deep melancholy and was ostracized by Liu's family. On returning to Sichuan, Liu was arranged to marry a second wife, Lady Li Zhuqian. In 1920, she gave birth to Liu's first child, a daughter named Liu Yuankai. Although she was politically-engaged and involved in her husband's work, she became infertile due to illness and reportedly gave her assent for Liu to be married a third time to bear a male heir. In 1924, he was arranged to marry his third wife, Yang Yunguang. His son, Liu Yuanyan, was born in 1928. According to his son, Liu's third marriage was arranged because he needed a "presentable" wife for social engagements as his military career advanced. Yang was also involved in Liu's work and was on cordial terms with Li Zhuqian. Both Li and Yang followed Liu during his retreat to Xikang, with Yang becoming one of his primary political partners.
To promote better consistency between a trial's objective and analysis methods, the International Committee for Harmonization of Technical Requirements for Pharmaceuticals for Human Use (ICH) has published a new international trial regulatory guidance in Nov 2019, the ICH E9(R1) Addendum on Estimands and Sensitivity Analysis in Clinical Trials. The guidance calls for clearly defining the research question of a trial by specifying its estimand. An estimand is a clear description of the treatment effect a trial aims to quantify. The guidance provides a structured framework for defining estimands, which consists of five attributes: (i) population of patients; (ii) treatment conditions being compared; (iii) the endpoint; (iv) the summary measure; and (v) how intercurrent events are handled. Tutorials on how to implement the estimand framework is available.
==== X-ray diffraction ==== A case study by Beale et al. involved preparation of iron phosphates and bismuth molybdate catalysts from an amorphous precursor gel. The study found that there were no intermediate phases in the reaction, and helped to determine kinetic and structural information. The article uses the dated term in-situ, but the experiment uses, in essence, an operando method. Although x-ray diffraction does not count as a spectroscopy method, it is often being used as an operando method in various fields, including catalysis.
Sources: en.wikipedia.org
The Canadian Penning Trap Mass Spectrometer (CPT) is one of the major pieces of experimental equipment that is installed on the ATLAS superconducting heavy-ion linac facility at the Physics Division of the Argonne National Laboratory. It was developed and operated by physicist Guy Savard and a collaboration of other scientists at Argonne, the University of Manitoba, McGill University, Texas A&M University and the State University of New York.
Wolpaw and Pinkerton turned down invitations to return to Valve early in the Alyx development. Instead, Valve recruited Rob Yescombe of The Invisible Hours, who worked on Alyx in 2017 and 2018. Yescombe's narrative was darker than previous Half-Life games, with scenes of dread, torture and horror. The antagonist was a female Combine officer named Hahn; in one proposed ending, Alyx would kill Hahn in revenge for torturing her father. Yescombe also proposed an ending in which Alyx and the G-Man would travel back in time to the events of the first Half-Life to prevent Freeman from triggering the alien invasion. After the company-wide playtest in 2018, feedback was overwhelmingly positive save for the story, which employees scored the lowest of any Valve game. Morasky described it as "dark, serious and laborious", likening it to a Zack Snyder superhero film. The designer Corey Peters said the feedback vindicated their misgivings. Valve initially planned to launch Alyx alongside its Index VR headset in June 2019, but delayed it to address the story. They re-enlisted Wolpaw and Pinkerton to rewrite the plot and dialogue while preserving the gameplay, along with Jake Rodkin and Sean Vanaman, who had joined when Valve acquired Campo Santo. Laidlaw, who retired in 2016, denied reports that he had provided consultation, saying he had confidence in Pinkerton and Wolpaw and that he did not want them "second-guessing" him. The new writing team identified three problems. First, the nature of a prequel meant that players knew the characters would survive, reducing suspense.
The MEN-1 syndrome often exhibits tumors of parathyroid glands, anterior pituitary, endocrine pancreas, and endocrine duodenum. Less frequently, neuroendocrine tumors of lung, thymus, and stomach or non-endocrine tumors such as lipomas, angiofibromas, and ependymomas are observed neoplasms. In a study of 12 sporadic carcinoid tumors of the lung, five cases involved inactivation of both copies of the MEN1 gene. Of the five carcinoids, three were atypical and two were typical. The two typical carcinoids were characterized by a rapid proliferative rate with a higher mitotic index and stronger Ki67 positivity than the other typical carcinoids in the study. Consequently, the carcinoid tumors with MEN1 gene inactivation in the study were considered to be characterized by more aggressive molecular and histopathological features than those without MEN1 gene alterations.
The differences in life span between species demonstrate the role of genetics in determining maximum life span ("rate of aging"). The records (in years) are these: for the common house mouse, 4 for the brown rat, 3.8 for dogs, 29 (see: List of longest-living dogs) for cats, 38 (see: List of longest-living cats) for common cranes, 43 for polar bears, 42 (see: Debby) for horses, 62 for Asian elephants, 86
Sources: en.wikipedia.org
==== Metals as catalytic sites ==== The metals in the MOF structure often act as Lewis acids. The metals in MOFs often coordinate to labile solvent molecules or counter ions which can be removed after activation of the framework. The Lewis acidic nature of such unsaturated metal centers can activate the coordinated organic substrates for subsequent organic transformations. The use of unsaturated metal centers was demonstrated in the cyanosilylation of aldehydes and imines by Makoto Fujita and coworkers in 2004. They reported MOF of composition {[Cd(4,4′-bpy)2(H2O)2] • (NO3)2 • 4H2O} which was obtained by treating linear bridging ligand 4,4′-bipyridine (bpy) with Cd(NO3)2. The Cd(II) centers in this MOF possess a distorted octahedral geometry having four pyridines in the equatorial positions, and two water molecules in the axial positions to form a two-dimensional infinite network. On activation, two water molecules were removed leaving the metal centers unsaturated and Lewis acidic. The Lewis acidic character of metal center was tested on cyanosilylation reactions of imine where the imine gets attached to the Lewis-acidic metal centre resulting in higher electrophilicity of imines. For the cyanosilylation of imines, most of the reactions were complete within 1 h affording aminonitriles in quantitative yield. Kaskel and coworkers carried out similar cyanosilylation reactions with coordinatively unsaturated metals in three-dimensional (3D) MOFs as heterogeneous catalysts.
By 1906, there were 61 Lodges in Cuba. Independent Lodges who did not desire to recognize the authority of the Grand Lodge still existed in the Eastern half of the island. The Grand Lodge of Cuba considered these Lodges to be clandestine and irregular, completely unwilling to "...submit to Masonic law and cooperate to maintain the high reputation which Cuban Masonry has won after years of struggle..." Between 1902 and 1905, fifty thousand Spaniards from the Iberian Peninsula gained citizenship and residency in the new Cuba. Some of these were willing to join the Grand Lodge of Cuba.
=== Saudi Arabia === In Saudi Arabia, an MD must pass the Saudi Medical License Exam (SMLE) to apply for medical residency programs. The competitiveness of residency programs varies by specialty and region, with Plastic Surgery, Ophthalmology, Dermatology, and ENT being the most competitive. Residency durations range from 3 to 7 years, depending on the specialty. All residency programs include an end-of-training medical exam, which is conducted in English, as a requirement for board certification.
=== Microcins === Microcins are all RiPPs produced by Enterobacteriaceae with a molecular weight <10 kDa. Many members of other RiPP families, such as microcin E492, microcin B17 (LAP) and microcin J25 (Lasso peptide) are also considered microcins. Instead of being classified based on posttranslational modifications or modifying enzymes, microcins are instead identified by molecular weight, native producer, and antibacterial activity. Microcins are either plasmid- or chromosome-encoded, but specifically have activity against Enerobacteriaceae. Because these organisms are also often producers of microcins, the gene cluster contains not only a precursor peptide and modification enzymes, but also a self-immunity gene to protect the producing strain, and genes encoding export of the natural product. Microcins have bioactivity against Gram-negative bacteria but usually display narrow-spectrum activity due to hijacking of specific receptors involved in the transport of essential nutrients.
The improved safety and tolerability profile of the SSRIs in patients with MDD, compared with TCAs and MAOIs, represented yet another important advance in the treatment of depression. Since the late 1980s, SSRIs have dominated the antidepressant drug market. Today, there is increased interest in antidepressant drugs with broader mechanisms of action that may offer improvements in efficacy and tolerability. In 1993, a new drug was introduced to the US market called venlafaxine, a serotonin–norepinephrine reuptake inhibitor. Venlafaxine was the first compound described in a new class of antidepressant substances called phenylethylamines. These substances are unrelated to TCA and other SSRIs. Venlafaxine blocks the neuronal reuptake of serotonin, norepinephrine, and, to a lesser extent, dopamine in the central nervous system. In contrast with several other antidepressant drugs, venlafaxine can induce a rapid onset of action mainly due to a subsequent norepinephrine reuptake inhibition. See timeline in figure 1.
Sources: en.wikipedia.org
The lyophilized powder is generally stored at -20 °C or lower, desiccated, and protected from light. Solutions are often aliquoted to avoid repeated freeze-thaw cycles. Specific stability data may vary by formulation and purity.
Mass spectrometry is commonly used to confirm molecular mass, while RP-HPLC estimates purity. These methods can be combined with amino acid analysis or NMR for further structural confirmation. A certificate of analysis alone does not guarantee independent verification.
Legality depends on the country and the intended use. In many places it is not approved as a drug and may be regulated as a research chemical. Buyers should check local laws and institutional policies before obtaining it.
Dihexa has been reported to activate hepatocyte growth factor/c-Met signaling in cell studies. This pathway is linked to synapse formation and neuronal remodeling. The exact molecular interactions are not fully understood.